Roche's Alecensa wins EU panel's nod against mutated lung cancer

ZURICH (Reuters) - Swiss drugmaker Roche's Alecensa has been recommended for approval in Europe as a first-line treatment for mutated lung cancer, a key European Medicines Agency (ESA) experts panel said on Friday.